首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1140728

全球旅行疫苗市場（旅行前疫苗）-2022-2029

Global Travelers Vaccines Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

旅遊業的增長是市場增長的驅動力

旅遊業的發展和旅行相關疾病的發病率激增是旅行者疫苗市場的主要增長因素。製藥和生物技術公司對新疫苗研發的投資增加，以及國際旅行者更多地採用疫苗，這些都推動了對旅行者疫苗的需求。此外，政府舉措的增加以及通過電子和印刷媒體提高認識是推動市場增長的因素。然而，缺乏疫苗製造專業知識和薄弱的冷供應鏈管理是阻礙市場增長的因素。

嚴重副作用的低風險也有助於市場增長。除了對胎兒產生嚴重副作用的極低風險外，各種非營利組織的適當教育和意識計劃也是支持市場增長的因素。新興國家和欠發達國家對疫苗外包的日益關注為推動旅行者疫苗市場提供了機會。由於出國旅遊人數的增加以及疫苗接種率的提高，預計會出現增長。

地理滲透

北美是預測期內的主要地區。

該研究按地區分析了全球市場的旅行疫苗市場，包括北美、歐洲、亞太地區、南美、中東和非洲。

按地區劃分，預計北美將在預測期內主導全球人類疫苗市場。在北美，預計聯合疫苗市場份額將增長，其次是重組疫苗和減毒疫苗市場。在歐洲，疫苗需求的增加和研發支出的增加正在推動旅行疫苗市場的發展。

此外，由於醫療基礎設施的改善和政府為實施教育和宣傳計劃而增加的支出，亞太地區已成為旅行疫苗的新興市場。在中東和非洲國家，醫療保健行業和經濟發展正在推動加強旅行者疫苗市場。然而，定價問題是製約市場增長的一個因素。沙特政府在該國實施了常規流感、流感和其他疫苗計劃，為旅行者的疫苗市場創造了機會。

競爭格局

由於主要食品品牌的存在，旅行者的疫苗市場競爭激烈。對全球市場增長做出貢獻的主要旅行疫苗公司有Baxter International, Abbott Laboratories, Crucell Vaccine, Pfizer, Emergent Biosolutions, Hoffman-La Roche, Dynavac Technologies, GSK Group, Shenzhen Kangtay Biological Products Co. Ltd., Takeda Pharmaceutical Company Limited (U.S.), Zydus Cadila等。主要參與者正在為旅行疫苗市場的全球增長採取新產品發布和擴張戰略。一些主要參與者正在遵循收購策略來擴展業務。例如，2021 年 12 月，全球 MedTech 領導者 Baxter 完成了對 Hillrom 的收購。此次收購加速了公司在全球範圍內改變醫療保健和推進患者護理的願景。Baxter 是一家臨床階段的生物製藥公司，以 156.00 美元現金收購 Hill-Rom 普通股的每股流通股，將收購價格定為 105 億美元。2022年6月，輝瑞完成了對ReViral的收購。此次收購幫助擴大了公司有前景的候選治療藥物組合，包括順納托韋，一種口服抑製劑，旨在阻斷 RSV 病毒與宿主細胞的融合。此次收購進一步證明了開創性科學的進步。2021年12月，輝瑞將以每股100美元的價格收購Arena Pharmaceuticals，這是一家臨床階段的公司，開髮用於治療多種免疫炎症性疾病的創新潛在療法，總股本價值約為67億美元。

COVID-19 對全球旅行疫苗市場的負面影響。

COVID-19 無疑阻礙了全球旅行疫苗的發展。由於各國政府實施的國際旅行禁令，2020 年的國際旅客人數有所減少。因此，對旅行者疫苗的需求減少，導致市場價值從 2020 年開始下降。

自 COVID-19 以來，旅遊業蓬勃發展，預計對健康和安全的日益增長的興趣將推動對旅行者疫苗的需求。由於這種大流行，旅行者疫苗在明年將經歷非常快速的增長。

全球旅行者疫苗市場報告提供對大約 56 個市場數據表、47 個數字和 170 頁的訪問。

Baxter International
- 公司簡介
- 產品組合和描述
- 主要亮點
- 財務摘要
Abbott Laboratories
Crucell Vaccines
Pfizer Inc.
Emergent BioSolutions
Hoffman-La Roche Ltd.
Dynavax Technologies Corporation
GSK group of companies
Shenzhen Kangtay Biological Products Co. Ltd.
Takeda Pharmaceuticals U.S.A. Inc
Zydus Cadila（List Not Exhaustive）

第 12 章重要注意事項

第 13 章數據管理

簡介目錄

Product Code: DMHCIT3104

Market Overview

Travelers Vaccines Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 8.60 % during the forecast period (2022-2029).

Vaccines are a biological preparation that aids in fighting against diseases and boosting immunity. It contains an agent related to a disease-causing organism and is made from a killed form of microbes. According to the World Health Organization (WHO), currently, licensed vaccines are available to avoid over twenty-five infections. The vaccine's effectiveness depends on disease pathophysiology, the stain of the vaccine, ethnicity, the schedule of the vaccination, and genetic predisposition. As globalization rises, international traveling will keep increasing, creating the demand for travel vaccines. Moreover, vaccines are broadly used as a preventive measure counter to known infectious diseases. The travelers are educated to adhere to the region-specific immunization plan. The number of diseases and viruses that have afflicted the sector has increased swiftly in the past few decades, and certainly, not enough vaccinations have been developed against them. The increased awareness has obliged people to take the necessary vaccinations without giving them a second thought.

Market Dynamics: Growing tourism and travel industry drives market growth

The growing touring industry and surge in the incidence of travel-related diseases are the major growth driver for the traveler vaccine market. Growing investment in the R&D of new vaccines by pharmaceutical and biotechnology companies and the growing adoption of vaccines by international travelers have prompted the demand for traveler vaccines. Furthermore, the growing government initiatives and rising awareness through electronic & print media are the factors that are expected to enhance the growth of the market. However, lack of expertise in the production of vaccines and weak cold supply chain management are the factors limiting the market's growth.

Also, the low risk of serious side effects helps to grow the market. Extreme low risks of serious side effects on the fetus, along with suitable educational & awareness programs through various nonprofit organizations, are factors that support the market growth. Rising inclinations for outsourcing vaccines in emerging and underdeveloped countries offer the opportunity to boost the traveler's vaccine market. It is expected to grow with the increase in outbound travel and vaccination coverage due to its awareness.

Market Segmentation: The tourist's segment will project the fastest growth in the market throughout the forecast period

Traveller's vaccines are further segmented based on an application that includes tourists, students, workers and others

The tourist segment is anticipated to grow with a high CAGR over the forecast period. World tourism organization stated that Global tourism experienced a mild 4% upturn in 2021, with 15 million more international tourist arrivals (overnight visitors) than in 2020. Europe and the Americas recorded the strongest results by region relative to 2020, with arrivals up 19% and 17%, respectively. Many of these travelers' journeys start in developed countries to regions with endemic diseases. Moreover, regulatory authorities globally have also instructed that travelers should be vaccinated before traveling to disease-prone regions.

Based on the type, the traveller's vaccines market has been classified into Meningococcal Vaccine, Japanese Encephalitis Vaccine, Yellow Fever Vaccine, Hepatitis Vaccine, Cholera Vaccine and Others.

Hepatitis Vaccine held significant share in the market. A key driver for the hepatitis vaccine market is the increasing prevalence of HBV infected populations, particularly in the WHO Western Pacific Region. Governments globally recognize the HBV vaccine as the only cost-effective way to primary infection prevention.

Geographical Penetration: North America is the dominating region during the forecast period.

Based on geography, the study analyzes the traveller's vaccines market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Geographically, North America is likely to dominate the human vaccines market in the global market over the forecast period. The combination vaccines segment is expected to expand at a high share in North America, followed by the recombinant and attenuated vaccines segments. In Europe, an increase in demand for vaccination and an increase in R&D expenditure boost the traveler's vaccines market.

Moreover, Asia Pacific is an emerging market for traveler's vaccines due to the improving healthcare infrastructure and rising government expenditures for organizing educational & awareness programs. In the Middle East and African countries, the advancement of the healthcare industry and economy helps to enhance travelers' vaccine market. However, affordability issues are factors restraining the market growth. The Government of Saudi Arabia operates routine vaccination programs for influenza, flu, and other vaccines in the country, generating an opportunity in the traveler's vaccine market.

Competitive Landscape:

The traveler's vaccines market is highly competitive, owing to the presence of big food brands. The key traveler's vaccines players which are contributing to the growth of the global market include Baxter International, Abbott Laboratories, Crucell Vaccines, Pfizer Inc., Emergent BioSolutions, Hoffman-La Roche Ltd., Dynavax Technologies Corporation, GSK group of companies, Shenzhen Kangtay Biological Products Co. Ltd., Takeda Pharmaceuticals U.S.A. Inc., Zydus Cadila, among others. The major players are adopting new product launches and expansion strategies for global growth in the traveler's vaccines market. Some key players follow acquisition strategies to expand their business. For instance, in December 2021, Baxter, a global MedTech leader, completed the acquisition of Hillrom. This acquisition accelerates the company's vision for transforming healthcare and advancing patients care worldwide. Baxter, a clinical-stage biopharmaceutical company, paid $156.00 in cash for each outstanding share of Hillrom common stock for a purchase price of $10.5 billion. In June 2022, Pfizer completed the acquisition with ReViral. This acquisition helped to expand a portfolio of promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block the fusion of the RSV virus to the host cell. This acquisition further demonstrated advancing pioneering science. In December 2021, Pfizer acquired Arena Pharmaceuticals, a clinical-stage company developing innovative potential therapies for treating several immuno-inflammatory diseases, for $100 per share in a total equity value of approximately $6.7 billion.

COVID-19 Impact: Negative impact on the global traveler's vaccines market.

COVID-19 has certainly hampered the growth of the traveler's vaccine globally. The ban on international traveling by the governments has declined the number of international visits in 2020. Therefore, the demand for traveler's vaccines declined and led to a downfall in the market value in 2020 and subsequent years.

Post COVID-19, it is expected that the travel and tourism industry get the boom, and the demand for traveler's vaccines also will gain traction due to increasing concern for health safety. Traveler's vaccines have a very rapid growth in the upcoming year due to this pandemic.

The global traveler's vaccines market report would provide an access to approximately 56 market data tables, 47 figures and 170 pages

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Type
3.2. Market Snippet by Application
3.3. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Growing tourism and travel industry
- 4.1.2. Restraints:
  - 4.1.2.1. Low risk of side effects
- 4.1.3. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Value Chain Analysis
5.4. PEST Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs
5.9. Patent Trends

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
7.3. Market Attractiveness Index, By Type Segment
- 7.3.1. Meningococcal Vaccine*
  - 7.3.1.1. Introduction
  - 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 7.3.2. Japanese Encephalitis Vaccine
- 7.3.3. Yellow Fever Vaccine
- 7.3.4. Hepatitis Vaccine
- 7.3.5. Cholera Vaccine
- 7.3.6. Others

8. By Application

8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
8.3. Market Attractiveness Index, By Application Segment
- 8.3.1. Tourists*
  - 8.3.1.1. Introduction
  - 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 8.3.2. Students
- 8.3.3. Workers
- 8.3.4. Others

9. By Region

9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.3. Market Attractiveness Index, By Region
9.4. North America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. U.S.
  - 9.4.5.2. Canada
  - 9.4.5.3. Mexico
9.5. Europe
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. Germany
  - 9.5.5.2. U.K.
  - 9.5.5.3. France
  - 9.5.5.4. Italy
  - 9.5.5.5. Spain
  - 9.5.5.6. Rest of Europe
9.6. South America
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.6.5.1. Brazil
  - 9.6.5.2. Argentina
  - 9.6.5.3. Rest of South America
9.7. Asia Pacific
- 9.7.1. Introduction
- 9.7.2. Key Region-Specific Dynamics
- 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 9.7.5.1. China
  - 9.7.5.2. India
  - 9.7.5.3. Japan
  - 9.7.5.4. Australia
  - 9.7.5.5. Rest of Asia Pacific
9.8. Middle East and Africa
- 9.8.1. Introduction
- 9.8.2. Key Region-Specific Dynamics
- 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Baxter International*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. Abbott Laboratories
11.3. Crucell Vaccines
11.4. Pfizer Inc.
11.5. Emergent BioSolutions
11.6. Hoffman-La Roche Ltd.
11.7. Dynavax Technologies Corporation
11.8. GSK group of companies
11.9. Shenzhen Kangtay Biological Products Co. Ltd.
11.10. Takeda Pharmaceuticals U.S.A. Inc
11.11. Zydus Cadila (List Not Exhaustive)